After Hours
There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours.
Stocks Info
This NASDAQ-listed company operates within the Biotechnology industry segment, falling under the Healthcare sector. The current market capitalization of Ionis Pharmaceuticals Inc is $5.49B. A total of 1.64 million shares were traded on the day, compared to an average of 1.45M shares.
In the most recent transaction, Swayze Eric sold 7,154 shares of IONS for 32.84 per share on Jan 16 ’25. After the transaction, the EVP Research now owns 45,670 company shares. In a previous transaction on Jan 16 ’25, Swayze Eric sold 22 shares at 32.70 per share. IONS shares that EVP Research owns now total 184.
Among the insiders who sold shares, Schneider Eugene disposed of 6,523 shares on Jan 16 ’25 at a per-share price of $32.79. This resulted in the EVP, Chf Clinical Develop Ofcr holding 58,508 shares of IONS after the transaction. In another insider transaction, O’NEIL PATRICK R. sold 7,360 shares at $32.83 per share on Jan 16 ’25. Company shares held by the EVP CLO & General Counsel now total 61,203.
Even though price targets are rarely accurate, they do tend to exert some kind of influence from time to time and are often considered important by markets. In terms of 52-week highs and lows, IONS has a high of $52.49 and a low of $31.40.
As of this writing, IONS has an earnings estimate of -$0.85 per share for the current quarter. EPS was calculated based on a consensus of 9.0 estimates, with a high estimate of -$0.7 per share and a lower estimate of -$1.04.
Balance Sheet Annually/Quarterly
In a balance sheet, you can see what assets and liabilities the company has, as well as how much equity investors have invested. These figures can be used to calculate a company’s financial ratios to give investors a better idea of its prospects. IONS’s latest balance sheet shows that the firm has $2.11B in Cash & Short Term Investments as of fiscal 2021. There were $1.25B in debt and $240.55M in liabilities at the time. Its Book Value Per Share was $4.20, while its Total Shareholder’s Equity was $771.74M.
Analysts Opinion
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for IONS is Buy with a score of 4.14.
